<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<?covid-19-tdm?>
<article article-type="research-article" dtd-version="2.3" xml:lang="EN" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Pharmacol.</journal-id>
<journal-title>Frontiers in Pharmacology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Pharmacol.</abbrev-journal-title>
<issn pub-type="epub">1663-9812</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">874637</article-id>
<article-id pub-id-type="doi">10.3389/fphar.2022.874637</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Pharmacology</subject>
<subj-group>
<subject>Original Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Network Pharmacology and Bioinformatics Analyses Identify Intersection Genes of Vitamin D3 and COVID-19 as Potential Therapeutic Targets</article-title>
<alt-title alt-title-type="left-running-head">Wang et al.</alt-title>
<alt-title alt-title-type="right-running-head">Potential Targets of VD3 Anti-STAD/COVID-19</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Wang</surname>
<given-names>Shanglin</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1676676/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Gao</surname>
<given-names>Huayu</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1774215/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wang</surname>
<given-names>Xiaoru</given-names>
</name>
<xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1774345/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ma</surname>
<given-names>Xiaoli</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/361473/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zhang</surname>
<given-names>Lulu</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1464269/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Xing</surname>
<given-names>Yuanxin</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1596727/overview"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Jia</surname>
<given-names>Yanfei</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<uri xlink:href="https://loop.frontiersin.org/people/469015/overview"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Wang</surname>
<given-names>Yunshan</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1320269/overview"/>
</contrib>
</contrib-group>
<aff id="aff1">
<sup>1</sup>
<institution>Research Center of Basic Medicine</institution>, <institution>Jinan Central Hospital</institution>, <institution>Shandong University</institution>, <addr-line>Jinan</addr-line>, <country>China</country>
</aff>
<aff id="aff2">
<sup>2</sup>
<institution>Research Center of Basic Medicine</institution>, <institution>Jinan Central Hospital</institution>, <institution>Shandong First Medical University</institution>, <addr-line>Jinan</addr-line>, <country>China</country>
</aff>
<aff id="aff3">
<sup>3</sup>
<institution>Department of Pediatric Surgery</institution>, <institution>The First Affiliated Hospital of Shandong First Medical University</institution>, <addr-line>Jinan</addr-line>, <country>China</country>
</aff>
<aff id="aff4">
<sup>4</sup>
<institution>Department of Traditional Chinese Medicine</institution>, <institution>Jinan Central Hospital</institution>, <institution>Shandong First Medical University</institution>, <addr-line>Jinan</addr-line>, <country>China</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>
<bold>Edited by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/103716/overview">Stefano Fiorucci</ext-link>, University of Perugia, Italy</p>
</fn>
<fn fn-type="edited-by">
<p>
<bold>Reviewed by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1003388/overview">Bruno Catalanotti</ext-link>, University of Naples Federico II, Italy</p>
<p>
<ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/717304/overview">Tlili Barhoumi</ext-link>, King Abdullah International Medical Research Center (KAIMRC), Saudi Arabia</p>
</fn>
<corresp id="c001">&#x2a;Correspondence: Yanfei Jia, <email>jiayanfei_@126.com</email>; Yunshan Wang, <email>zxsyswys@126.com</email>
</corresp>
<fn fn-type="other">
<p>This article was submitted to Gastrointestinal and Hepatic Pharmacology, a section of the journal Frontiers in Pharmacology</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>28</day>
<month>04</month>
<year>2022</year>
</pub-date>
<pub-date pub-type="collection">
<year>2022</year>
</pub-date>
<volume>13</volume>
<elocation-id>874637</elocation-id>
<history>
<date date-type="received">
<day>12</day>
<month>02</month>
<year>2022</year>
</date>
<date date-type="accepted">
<day>11</day>
<month>04</month>
<year>2022</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2022 Wang, Gao, Wang, Ma, Zhang, Xing, Jia and Wang.</copyright-statement>
<copyright-year>2022</copyright-year>
<copyright-holder>Wang, Gao, Wang, Ma, Zhang, Xing, Jia and Wang</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract>
<p>
<bold>Purpose:</bold> The persistent pandemic of coronavirus disease 2019 (COVID-19), the discovery of gastrointestinal transmission routes and the possible susceptibility of cancer patients to COVID-19 have forced us to search for effective pathways against stomach adenocarcinoma (STAD)/COVID-19. Vitamin D3 (VD3) is a steroid hormone with antiviral, anti-inflammatory and immunomodulatory properties. This study aimed to evaluate the possible functional role and potential mechanisms of action of VD3 as an anti-COVID-19 and anti- STAD.</p>
<p>
<bold>Methods:</bold> Clinicopathological analysis, enrichment analysis and protein interaction analysis using bioinformatics and network pharmacology methods. Validate the binding activity of VD3 to core pharmacological targets and viral crystal structures using molecular docking.</p>
<p>
<bold>Results:</bold> We revealed the clinical characteristics of STAD/COVID-19 patients. We also demonstrated that VD3 may be anti- STAD/COVID-19 through antiviral, anti-inflammatory, and immunomodulatory pathways. Molecular docking results showed that VD3 binds well to the relevant targets of COVID-19, including the spike RBD/ACE2 complex and main protease (Mpro, also known as 3CLpro). We also identified five core pharmacological targets of VD3 in anti-STAD/COVID-19 and validated the binding activity of VD3 to PAI1 by molecular docking.</p>
<p>
<bold>Conclusion:</bold> This study reveals for the first time that VD3 may act on disease target gene <italic>SERPINE1</italic> through inflammatory and viral related signaling pathways and biological functions for the therapy of STAD/COVID-19. This may provide a new idea for the use of VD3 in the treatment of STAD/COVID-19.</p>
</abstract>
<kwd-group>
<kwd>gastric cancer</kwd>
<kwd>COVID-19</kwd>
<kwd>vitamin D3</kwd>
<kwd>calcitriol</kwd>
<kwd>network pharmacology</kwd>
<kwd>bioinformatics analyses</kwd>
<kwd>molecular docking</kwd>
</kwd-group>
<contract-sponsor id="cn001">National Natural Science Foundation of China<named-content content-type="fundref-id">10.13039/501100001809</named-content>
</contract-sponsor>
</article-meta>
</front>
<body>
<sec id="s1">
<title>Introduction</title>
<p>The coronavirus disease 2019 (COVID-19), currently caused by the infectious severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2), continues to place unprecedented strain on healthcare systems around the world. As of February 7, 2022, the number of patients has reached 396,252,002, with at least 5.7 million deaths. Unfortunately there is no specific drug for this deadly disease (<xref ref-type="bibr" rid="B51">Tang et al., 2020</xref>). Therefore, there is an urgent need for screening and validation of potential anti-COVID-19 targets or drugs. The clinical syndromes in COVID-19 patients usually present as respiratory symptoms, but there is increasing evidence that COVID-19 patients are also accompanied by gastrointestinal (GI) symptoms. And abdominal pain, diarrhea and ulcers are more frequently seen in patients in the intensive care unit than in those in the general care unit (<xref ref-type="bibr" rid="B35">Lin et al., 2020</xref>; <xref ref-type="bibr" rid="B44">Pan et al., 2020</xref>). It has been shown that SARS-CoV-2 can also be detected in adult stool samples and air samples from patients toilet areas (<xref ref-type="bibr" rid="B36">Liu et al., 2020</xref>; <xref ref-type="bibr" rid="B60">Zhang et al., 2020</xref>). And that adult gastric-like organs are more susceptible to infection after differentiation (<xref ref-type="bibr" rid="B17">Giobbe et al., 2021</xref>). This suggests that the stomach may have an active role in fecal-oral SARS-CoV-2 transmission. Furthermore, it has been shown that cancer patients are more likely to be infected with COVID-19 and have a more severe course of infection than non-cancer patients, due to a state of systemic immunosuppression caused by malignancy and anticancer therapy. As a result, these patients may be at increased risk of COVID-19 infection and have a poorer prognosis (<xref ref-type="bibr" rid="B34">Liang et al., 2020</xref>). Gastric cancer is one of the most common cancers and the third leading cause of cancer-related deaths worldwide (<xref ref-type="bibr" rid="B1">Arnold et al., 2020</xref>). Among them, the incidence of stomach adenocarcinoma (STAD) accounts for 95% of gastric malignancies. Therefore, effective treatment is urgently needed for COVID-19 patients, especially for STAD patients infected with a novel coronavirus (SARS-COV-2), which may be a new idea to improve patient survival and cut off the fecal-oral transmission route.</p>
<p>Vitamin D3 (VD3) is often used to improve overall health and is a precursor to the potent steroid hormone calcitriol 1,25 dihydroxy VD3 [1,25 (OH) 2D3]. And there is growing evidence that VD3 levels correlate with the risk of a variety of cancers (<xref ref-type="bibr" rid="B9">Feldman et al., 2014</xref>), including colon (<xref ref-type="bibr" rid="B45">Pereira et al., 2012</xref>), prostate (<xref ref-type="bibr" rid="B43">Mondul et al., 2016</xref>; <xref ref-type="bibr" rid="B10">Ferrer-Mayorga et al., 2017</xref>) and breast (<xref ref-type="bibr" rid="B50">Swami et al., 2000</xref>) cancers. Studies have also shown that VD3 deficiency is associated with a poor prognosis in gastric cancer (<xref ref-type="bibr" rid="B3">Bao et al., 2014</xref>). In particular, its deficiency is associated with increased susceptibility to infectious diseases (<xref ref-type="bibr" rid="B40">Martineau et al., 2019</xref>). Furthermore, treatment with calcitriol resulted in hepatitis C virus (HCV) suppression (<xref ref-type="bibr" rid="B13">Gal-Tanamy et al., 2011</xref>). This suggests that VD3 has a natural and direct antiviral effect. Interestingly, we also found evidence that VD3 against helicobacter pylori (<italic>H. pylori</italic>) and calcitriol showed beneficial anti-inflammatory effects in cancer (<xref ref-type="bibr" rid="B27">Krishnan and Feldman, 2011</xref>; <xref ref-type="bibr" rid="B20">Hu et al., 2019</xref>; <xref ref-type="bibr" rid="B61">Zhou et al., 2020</xref>). Particularly, VD3 was found to increase the expression of angiotensin-converting enzyme (ACE2), the functional receptor of SARS-CoV-2. Furthermore, studies suggested the possible protective role of VD3 on lung by inducing ACE2/Ang-(1-7)/MasR axis activity and inhibiting renin and ACE/Ang II/AT1R axis (<xref ref-type="bibr" rid="B57">Xu et al., 2017</xref>; <xref ref-type="bibr" rid="B14">Ganji et al., 2020</xref>). Although research findings have shown a correlation between low vitamin D levels and risk of death and COVID-19 infection (<xref ref-type="bibr" rid="B39">Maghbooli et al., 2020</xref>; <xref ref-type="bibr" rid="B42">Merzon et al., 2020</xref>), there is no consensus on the role of VD3 in COVID-19 outcomes (<xref ref-type="bibr" rid="B5">Cannata-And&#xed;a et al., 2022</xref>). Therefore, the pharmacological targets and mechanisms of VD3 or calcitriol against STAD/COVID-19 remain to be studied in detail.</p>
<p>Based on public databases and publicly available data, network pharmacology plays an important role in discovering biologically active ingredients, predicting drug targets, and analyzing drug mechanisms of action (<xref ref-type="bibr" rid="B19">Hopkins, 2008</xref>). In this study, bioinformatics and network pharmacology strategies, combined with the molecular docking approach, were used to explore the active components and potential targets of VD3 against STAD/COVID-19 for network visualization. We also created a flow chart to demonstrate the mechanism of VD3 resistance to STAD/COVID-19.</p>
</sec>
<sec sec-type="materials|methods" id="s2">
<title>Materials and Methods</title>
<sec id="s2-1">
<title>Identification of STAD/COVID-19&#x2013;Associated Genes</title>
<p>Transcriptome profiles of STAD patients were downloaded from The Cancer Genome Atlas (TCGA) database in November 2021. The differential genes in STAD were screened and obtained using the &#x2018;limma&#x2019; package of R-language Bioconductor. Furthermore, genes related to COVID-19 were selected from the OMIM database, Genecard database, KEGG and NCBI databases. Finally, these genes were compared to obtain the overlapping genes in STAD and COVID-19 (<xref ref-type="bibr" rid="B32">Li et al., 2020</xref>; <xref ref-type="bibr" rid="B31">Li et al., 2021a</xref>).</p>
</sec>
<sec id="s2-2">
<title>Collection of VD3 Related Genes</title>
<p>VD3-related genes were collected from accessible online tools, such as Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP), Swiss Target Prediction, TargetNet and Drugbank. Protein-gene name conversion was then performed using the protein database UniProt. Finally, a list of related genes was obtained by removing duplicates of these genes.</p>
</sec>
<sec id="s2-3">
<title>Clinicopathological Analysis of STAD and COVID-19&#x2013;Associated Genes</title>
<p>The correlation of STAD/COVID-19-related genes with survival in STAD/COVID-19 patients was analyzed in the &#x2018;survival package&#x2019; of the R package. Prognostic analysis of STAD/COVID-19 patients was performed using univariate and multivariate Cox proportional hazards regression. In addition, we analyzed the different characteristics of patients with STAD/COVID-19 (<xref ref-type="bibr" rid="B11">Fisher and Lin, 1999</xref>).</p>
</sec>
<sec id="s2-4">
<title>Enrichment Analyses and Network Visualization</title>
<p>Using R-language packages, including &#x2018;ClusterProfiler&#x27;, &#x2018;org.Hs.eg.Db&#x2019;, &#x2018;pathview&#x2019;, and &#x2018;GOplot&#x2019;, etc. for enrichment analysis and visualization of intersecting genes by Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG). GO enrichment analysis annotated the mechanism of action of target genes in three parts: biological process (BP), cellular composition (CC) and molecular function (MF), and analyzed the top ten entries of each part according to their <italic>p</italic> values. KEGG enrichment analysis was performed to annotate the signaling pathways in which the target genes were involved.</p>
</sec>
<sec id="s2-5">
<title>Identifying Core Targets of VD3 Against STAD/COVID-19</title>
<p>Protein-protein interaction network (PPI) and TSV files were obtained by importing the intersecting genes into the STRING database. Next, the top five proteins of the network in terms of attribute ranking were obtained using the MCC calculation method of the cytoHubba plugin in Cytoscape software (<xref ref-type="bibr" rid="B8">Chin et al., 2014</xref>).</p>
</sec>
<sec id="s2-6">
<title>Molecular Docking</title>
<p>The protein structures of COVID-19 associated proteins and target proteins were obtained from the PDB database (<ext-link ext-link-type="uri" xlink:href="https://www.rcsb.org">https://www.rcsb.org/</ext-link>) (<xref ref-type="bibr" rid="B59">Zardecki et al., 2022</xref>). The molecular structures of VD3 and Calcitriol were obtained from the PubChem database (<ext-link ext-link-type="uri" xlink:href="https://pubchem.ncbi.nlm.nih.gov">https://pubchem.ncbi.nlm.nih.gov/</ext-link>) (<xref ref-type="bibr" rid="B31">Li et al., 2021a</xref>). The corresponding proteins and small molecules were processed and docked using Discovery studio-2019 (DS). To ensure the accuracy of the docking prediction results, we used DeepSite to predict the possible docking pockets of the target proteins. DeepSite is freely available at <ext-link ext-link-type="uri" xlink:href="http://www.playmolecule.org">www.playmolecule.org</ext-link> (<xref ref-type="bibr" rid="B23">Jim&#xe9;nez et al., 2017</xref>). DeepSite considers various molecular descriptors related to the protein through the 3D-deep convolutional neural networks (DCNNs) validated using an extensive test set based on over 7,000 proteins from the scPDB database (<xref ref-type="bibr" rid="B25">Kellenberger et al., 2006</xref>; <xref ref-type="bibr" rid="B23">Jim&#xe9;nez et al., 2017</xref>). The cartesian coordinates of the center of the binding pocket found by DeepSite were used to define site in the DS with a radius of 12. And for other parameters, defaults were used. CDOCKER was used for small molecular-protein docking, Top Hit was set to 10, Pose Cluster Radius was set to 0.5. Finally, the interaction and binding modes of the active compounds were visualized and analyzed using PyMoL-2.1.0 and DS.</p>
</sec>
</sec>
<sec sec-type="results" id="s3">
<title>Results</title>
<sec id="s3-1">
<title>Identification of STAD/COVID-19 Target Genes</title>
<p>The flow of the study was exhibited in <xref ref-type="fig" rid="F1">Figure 1</xref>. From The Cancer Genome Atlas (TCGA) database, we obtained 32 normal samples and 375 tumor samples. When duplicated genes were excluded from all samples, the obtained genes were processed with the egdeR package for normalization and differential expression analysis. An adjusted <italic>p</italic>-value of &#x3c; 0.05 and a fold change value higher than 1.5 was used to indicate genes that were significantly differentially expressed. We obtained 1,439 differentially expressed genes (DEGs) after analysis and mapped the volcano plot (<xref ref-type="fig" rid="F2">Figure 2A</xref>). After that, we collected 2,537 genes associated with COVID-19 from the Genecard, OMIM, KEGG and NCBI databases by the method of network pharmacology. Comparing these two gene clusters, we identified 137 intersection genes for STAD and COVID-19 (<xref ref-type="fig" rid="F2">Figure 2B</xref>). Of them, 71 were upregulated, and the others were downregulated (<xref ref-type="fig" rid="F2">Figure 2C</xref>).</p>
<fig id="F1" position="float">
<label>FIGURE 1</label>
<caption>
<p>Workflow to investigate the anti-STAD/COVID-19 action and mechanism of vitamin D3.</p>
</caption>
<graphic xlink:href="fphar-13-874637-g001.tif"/>
</fig>
<fig id="F2" position="float">
<label>FIGURE 2</label>
<caption>
<p>Identification of STAD/COVID-19 target genes. <bold>(A)</bold> Volcano map of differential gene expression associated with STAD. <bold>(B)</bold> Venn diagram depicting intersecting genes in STAD/COVID-19. <bold>(C)</bold> Volcano plot of differential gene expression of STAD and COVID-19 intersecting genes.</p>
</caption>
<graphic xlink:href="fphar-13-874637-g002.tif"/>
</fig>
</sec>
<sec id="s3-2">
<title>Clinicopathological Analysis of STAD/COVID-19-Related Genes</title>
<p>To understand the correlation between STAD/COVID-19-related genes and prognosis, univariate and multifactorial Cox analyses were performed on 137 DEGs. First, univariate Cox analysis identified 15 genes that were significantly (<italic>p</italic> &#x3c; 0.05) associated (<xref ref-type="table" rid="T1">Table 1</xref>). However, multivariate Cox analysis identified 4 of these genes, including <italic>KIT</italic>, <italic>HBA1</italic>, <italic>SERPINE1</italic> and <italic>FKBP10</italic> (<xref ref-type="table" rid="T2">Table 2</xref>). Results in <xref ref-type="table" rid="T2">table 2</xref> showed that the 4 genes were bad prognostic factors. In addition, hazard ratios (HR) and 95% confidence intervals (CI) for risk scores from univariate Cox (uni-Cox) regression was 1.21 and 1.136&#x2013;1.29, respectively, (<italic>p</italic> &#x3c; 0.001). In comparison, the values of multivariate Cox (multi-Cox) regression were 1.189 and 1.115&#x2013;1.268, respectively, (<italic>p</italic> &#x3c; 0.001) (<xref ref-type="sec" rid="s12">Supplementary Figures S1A,B</xref>). In addition, we found two other independent prognostic parameters: age (1.033 and 1.015&#x2013;1.052; <italic>p</italic> &#x3c; 0.001) and stage (1.586 and 1.115&#x2013;1.268; <italic>p</italic> &#x3c; 0.001) (<xref ref-type="sec" rid="s12">Supplementary Figure S1B</xref>).</p>
<table-wrap id="T1" position="float">
<label>TABLE 1</label>
<caption>
<p>Univariate Cox proportional hazards regression analysis.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th align="left">GENE</th>
<th align="center">HR</th>
<th align="center">HR.95L</th>
<th align="center">HR.95H</th>
<th align="center">
<italic>p</italic>-value</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td align="left">
<italic>ADAMTS1</italic>
</td>
<td align="char" char=".">1.020758</td>
<td align="char" char=".">1.005256</td>
<td align="char" char=".">1.036498</td>
<td align="char" char=".">0.008505</td>
</tr>
<tr>
<td align="left">
<italic>AGT</italic>
</td>
<td align="char" char=".">1.002566</td>
<td align="char" char=".">1.00059</td>
<td align="char" char=".">1.004546</td>
<td align="char" char=".">0.010895</td>
</tr>
<tr>
<td align="left">
<italic>APOB</italic>
</td>
<td align="char" char=".">1.007883</td>
<td align="char" char=".">1.000705</td>
<td align="char" char=".">1.015113</td>
<td align="char" char=".">0.031303</td>
</tr>
<tr>
<td align="left">
<italic>CSF2</italic>
</td>
<td align="char" char=".">1.043598</td>
<td align="char" char=".">1.000148</td>
<td align="char" char=".">1.088935</td>
<td align="char" char=".">0.049207</td>
</tr>
<tr>
<td align="left">
<italic>CXCR2</italic>
</td>
<td align="char" char=".">1.06722</td>
<td align="char" char=".">1.001008</td>
<td align="char" char=".">1.137811</td>
<td align="char" char=".">0.046503</td>
</tr>
<tr>
<td align="left">
<italic>CYBRD1</italic>
</td>
<td align="char" char=".">1.00769</td>
<td align="char" char=".">1.00057</td>
<td align="char" char=".">1.014861</td>
<td align="char" char=".">0.03422</td>
</tr>
<tr>
<td align="left">
<italic>ERBB2</italic>
</td>
<td align="char" char=".">1.00069</td>
<td align="char" char=".">1.000034</td>
<td align="char" char=".">1.001348</td>
<td align="char" char=".">0.039318</td>
</tr>
<tr>
<td align="left">
<italic>F5</italic>
</td>
<td align="char" char=".">1.012415</td>
<td align="char" char=".">1.000812</td>
<td align="char" char=".">1.024152</td>
<td align="char" char=".">0.035911</td>
</tr>
<tr>
<td align="left">
<italic>FKBP10</italic>
</td>
<td align="char" char=".">1.001062</td>
<td align="char" char=".">1.00017</td>
<td align="char" char=".">1.001955</td>
<td align="char" char=".">0.019678</td>
</tr>
<tr>
<td align="left">
<italic>HBA1</italic>
</td>
<td align="char" char=".">1.024083</td>
<td align="char" char=".">1.008183</td>
<td align="char" char=".">1.040234</td>
<td align="char" char=".">0.002876</td>
</tr>
<tr>
<td align="left">
<italic>KIT</italic>
</td>
<td align="char" char=".">1.051295</td>
<td align="char" char=".">1.01247</td>
<td align="char" char=".">1.091608</td>
<td align="char" char=".">0.009175</td>
</tr>
<tr>
<td align="left">
<italic>MKI67</italic>
</td>
<td align="char" char=".">0.983793</td>
<td align="char" char=".">0.968023</td>
<td align="char" char=".">0.99982</td>
<td align="char" char=".">0.0475</td>
</tr>
<tr>
<td align="left">
<italic>P3H4</italic>
</td>
<td align="char" char=".">1.002645</td>
<td align="char" char=".">1.000167</td>
<td align="char" char=".">1.00513</td>
<td align="char" char=".">0.036413</td>
</tr>
<tr>
<td align="left">
<italic>S100A12</italic>
</td>
<td align="char" char=".">1.005972</td>
<td align="char" char=".">1.000591</td>
<td align="char" char=".">1.011382</td>
<td align="char" char=".">0.02956</td>
</tr>
<tr>
<td align="left">
<italic>SERPINE1</italic>
</td>
<td align="char" char=".">1.001841</td>
<td align="char" char=".">1.000532</td>
<td align="char" char=".">1.003153</td>
<td align="char" char=".">0.005846</td>
</tr>
</tbody>
</table>
</table-wrap>
<table-wrap id="T2" position="float">
<label>TABLE 2</label>
<caption>
<p>Multivariate Cox proportional hazards regression analysis.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th align="left">GENE</th>
<th align="center">coef</th>
<th align="center">HR</th>
<th align="center">HR.95L</th>
<th align="center">HR.95H</th>
<th align="center">
<italic>p</italic>-value</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td align="left">
<italic>KIT</italic>
</td>
<td align="char" char=".">0.056912</td>
<td align="char" char=".">1.058563</td>
<td align="char" char=".">1.017629</td>
<td align="char" char=".">1.101143</td>
<td align="char" char=".">0.004677</td>
</tr>
<tr>
<td align="left">
<italic>HBA1</italic>
</td>
<td align="char" char=".">0.024432</td>
<td align="char" char=".">1.024733</td>
<td align="char" char=".">1.006387</td>
<td align="char" char=".">1.043413</td>
<td align="char" char=".">0.008033</td>
</tr>
<tr>
<td align="left">
<italic>SERPINE1</italic>
</td>
<td align="char" char=".">0.001765</td>
<td align="char" char=".">1.001767</td>
<td align="char" char=".">1.000222</td>
<td align="char" char=".">1.003314</td>
<td align="char" char=".">0.024971</td>
</tr>
<tr>
<td align="left">
<italic>FKBP10</italic>
</td>
<td align="char" char=".">0.001049</td>
<td align="char" char=".">1.001049</td>
<td align="char" char=".">1.000091</td>
<td align="char" char=".">1.002009</td>
<td align="char" char=".">0.031815</td>
</tr>
</tbody>
</table>
</table-wrap>
<p>We investigated the correlation between the expression of the four genes obtained in <xref ref-type="table" rid="T2">Table 2</xref> and the prognosis of STAD patients through the GEPIA online platform (<ext-link ext-link-type="uri" xlink:href="http://gepia2.cancer-pku.cn/">http://gepia2.cancer-pku.cn/&#x23;index</ext-link>). We found that STAD patients with lower <italic>SERPINE1</italic> levels exhibited significantly longer overall survival (OS) and disease-free survival (DFS) than those with higher <italic>SERPINE1</italic> levels (<italic>p</italic> &#x3c; 0.01). Likewise, STAD patients with lower levels of <italic>FKBP10</italic> or <italic>KIT</italic> showed a better prognosis (<italic>p</italic> &#x3c; 0.05, <xref ref-type="fig" rid="F3">Figure 3</xref>). The above results indicated that <italic>SERPINE1</italic>, <italic>FKBP10</italic> and <italic>KIT</italic> were closely related to the prognosis of STAD patients.</p>
<fig id="F3" position="float">
<label>FIGURE 3</label>
<caption>
<p>Overall survival and disease-free survival analysis of STAD/COVID-19-related genes in GEPIA datasets. <bold>(A)</bold>: SERPINE1, <bold>(B)</bold>: FKBP10, <bold>(C)</bold>: KIT. <italic>P</italic> &#x3c; 0.05 was considered statistically significant.</p>
</caption>
<graphic xlink:href="fphar-13-874637-g003.tif"/>
</fig>
</sec>
<sec id="s3-3">
<title>Identification of Potential Target Genes of VD3 Against STAD/COVID-19</title>
<p>We downloaded the 3D molecular structure and SMILES [CC(C)CCC&#x200b;C(C)C1CCC2C1(CCC&#x200b;C2 &#x3d; CC &#x3d; C3CC(CCC3 &#x3d; C)O)C] of VD3 from PubChem. The PubChem CID of VD3 is 5280795. The chemical formula and molecular weight of VD3 are C<sub>27</sub>H<sub>44</sub>O and 384.6&#xa0;g/mol, respectively. Then, a portion of the major target genes of VD3 were searched from the Swiss Target Prediction databases and TargetNet web server. Meanwhile, we also collected a portion of VD3-related target genes from GeneCards databases and TCMSP databases. After name conversion of the targets and removing duplicates, 2274 VD3-related target genes were obtained. Identification of 60 VD3 intersecting genes against STAD/COVID-19 after overlap of STAD/COVID-19-related genes with VD3-related target genes (<xref ref-type="fig" rid="F4">Figure 4A</xref>, <xref ref-type="sec" rid="s12">Supplementary Table S1</xref>). By the same method, we identified 52 calcitriol anti- STAD/COVID-19 intersecting genes <xref ref-type="sec" rid="s12">Supplementary Figure S2A</xref>.</p>
<fig id="F4" position="float">
<label>FIGURE 4</label>
<caption>
<p>Functional characterization of VD3 against STAD/COVID-19. <bold>(A)</bold> Venn diagram of VD3 and STAD/COVID-19 Intersecting genes. <bold>(B)</bold> GO analysis of intersecting genes of VD3 and STAD/COVID-19. <bold>(C)</bold> KEGG pathway enrichment analysis of intersecting genes of VD3 and STAD/COVID-19.</p>
</caption>
<graphic xlink:href="fphar-13-874637-g004.tif"/>
</fig>
<p>For a further, more comprehensive and macroscopic understanding of the biological functions of the intersection genes, we performed GO functional enrichment analysis and KEGG pathway enrichment analysis on these 60 genes. The results showed that VD3 affected 477 biological processes (BP), 32 cellular components (CC), 56 molecular functions (MF) (<italic>p</italic> &#x3c; 0.05, <xref ref-type="sec" rid="s12">Supplementary Table S2</xref>), involving response to lipopolysaccharide, response to molecule of bacterial origin, cell chemotaxis, leukocyte migration, and other biological processes; vesicle lumen, secretory granule lumen, cytoplasmic vesicle lumen, and other cellular components; receptor ligand activity, signaling receptor activator activity, and other molecular functions (<xref ref-type="fig" rid="F4">Figure 4B</xref>). The 10 biological process terms with the lowest adjusted <italic>p</italic> values in each category are shown in the dot plot. And the above results implied the possible main functions of the 60 intersecting genes.18 signaling pathways associated with all intersection genes were obtained by the KEGG pathway enrichment analysis (<italic>p</italic> &#x3c; 0.05, <xref ref-type="sec" rid="s12">Supplementary Table S3</xref>), and shown in dot plot according to the gene ratios (<xref ref-type="fig" rid="F4">Figure 4C</xref>). The results showed 60 intersecting genes focused on transcriptional misregulation in cancer, coronavirus disease-COVID-19, IL-17 signaling pathway and cytokine-cytokine receptor interaction pathway. The above results implied the main pathways involved in the 60 intersecting genes. Notably, <italic>SERPINE1</italic> and <italic>FKBP10</italic> genes were found in the hematopoietic cell lineage (hsa04640), acute myeloid leukemia (hsa05221) and complement and coagulation cascades (hsa04610) pathways. Taken together, these results demonstrated that VD3 and calcitriol (<xref ref-type="sec" rid="s12">Supplementary Figures S2B,C</xref>) act on COVID-19 and STAD through multiple pathways, multiple targets, and overall cooperation.</p>
</sec>
<sec id="s3-4">
<title>Identification of Core Targets of VD3 Against STAD and COVID-19</title>
<p>Determination of the 60 intersecting target gene-mediated PPI-networks of VD3 against COVID19/STAD using STRING analysis (<xref ref-type="fig" rid="F5">Figure 5A</xref>). Ranked network centrality nodes using the Maximal Clique Centrality (MCC) algorithm of the cytoHubba plugin with 60 intersection genes input to Cytoscape software. <xref ref-type="fig" rid="F5">Figure 5B</xref> showed the connectivity of the top five hub nodes in the network, the darker the node color means the higher the score. The results showed that the top five core target genes were <italic>IL1A</italic>, <italic>CXCL8</italic>, <italic>ALB</italic>, <italic>CSF2</italic> and <italic>SERPINE1</italic>. Furthermore, the hub nodes appeared in 16 pathways in <xref ref-type="fig" rid="F4">Figure 4C</xref> except for neutrophil extracellular trap formation and renin-angiotensin system pathways (<xref ref-type="sec" rid="s12">Supplementary Table S3</xref>).</p>
<fig id="F5" position="float">
<label>FIGURE 5</label>
<caption>
<p>Identification of core targets of VD3 against STAD and COVID-19. <bold>(A)</bold> STRING analysis of VD3 and STAD/COVID-19 intersecting genes. <bold>(B)</bold> Cytoscape analysis representing the gene interaction networks associated with VD3 anti-STAD/COVID-19. The top five hub genes&#x2014;<italic>CXCL8</italic>, <italic>CSF2</italic>, <italic>ALB</italic>, <italic>SERPINE1</italic> and <italic>IL1A</italic>&#x2014;are highlighted. <bold>(C)</bold> Diagram of receptor and ligand (VD3 or calcitriol).</p>
</caption>
<graphic xlink:href="fphar-13-874637-g005.tif"/>
</fig>
</sec>
<sec id="s3-5">
<title>Confirmation of VD3 Binding to STAD/COVID-19 Targets</title>
<p>Molecular docking was performed to visualize the patterns of interactions between the VD3 and the identified STAD/COVID-19 target proteins (<xref ref-type="fig" rid="F5">Figure 5C</xref>). We selected the SARS-COV-2 Spike RBD/ACE2 complex (PDB:6LZG) (<xref ref-type="bibr" rid="B54">Wierbowski et al., 2021</xref>) and main protease complex crystal structure of COVID-19 (PDB:5R84) (<xref ref-type="bibr" rid="B31">Li et al., 2021a</xref>) for molecular docking analysis with VD3. These crystal structures of the COVID-19 were collected from the PDB database (<ext-link ext-link-type="uri" xlink:href="http://www.rcsb.org/">http://www.rcsb.org</ext-link>). In order to predict the VD3-protein binding site, we performed binding pocket simulations of the target structures in this study by referring to the methods applied in the literature for natural product binding mode studies (<xref ref-type="bibr" rid="B49">Singh et al., 2021</xref>). In this paper, pockets were predicted using DeepSite and pocket locations were visualized using PyMoL (<xref ref-type="sec" rid="s12">Supplementary Figure S4</xref>). <xref ref-type="sec" rid="s12">Supplementary Table S4</xref> shows the scores for each prediction pocket.</p>
<p>Two cavity coordinates were detected by DeepSite in SARS-CoV-2 RBD/ACE2 (<xref ref-type="sec" rid="s12">Supplementary Figure S4A</xref>). We believed that interference in protein-protein interactions occurs mainly on the protein surface, and the key amino acid residue (Y41, K353, N501, Y505) reported in the literature that affects the binding of Spike (S) glycoprotein to ACE2 is located near cavity 2 (<xref ref-type="sec" rid="s12">Supplementary Figure S5</xref>) (<xref ref-type="bibr" rid="B29">Lan et al., 2020</xref>), so we selected cavity 2 for molecular docking. Our results showed that the hydroxyl group of VD3 forms hydrogen bond with D405 of SARS-CoV-2 RBD/ACE2, and hydrophobic interactions were also found. (<xref ref-type="fig" rid="F6">Figure 6A</xref>). Notably, the binding pocket is located in the protein-protein interaction region of the SARS-COV-2 Spike RBD/ACE2 complex. Based on the docking results, we hypothesized that VD3 may play an inhibitory role in the binding of the Spike glycoprotein of SARS-CoV-2 to the host angiotensin-converting enzyme 2 (ACE2) receptor. We also did the molecular docking of calcitriol with SARS-CoV-2 RBD/ACE2. The results showed that the hydroxyl groups of calcitriol form hydrogen bonds with G504 and Q325 of SARS-CoV-2 RBD/ACE2 (<xref ref-type="sec" rid="s12">Supplementary Figure S6A</xref>). Four cavity coordinates were detected by DeepSite in SARS-CoV-2 Mpro. We selected the highest scoring cavity 2 for molecular docking (<xref ref-type="sec" rid="s12">Supplementary Figure S4B</xref>). The results showed that the hydroxyl group of VD3 forms hydrogen bond with E166 of Mpro, and the hydrophobic interactions were also found. (<xref ref-type="fig" rid="F6">Figure 6B</xref>). Similarly, we did the molecular docking of calcitriol with Mpro. The results showed that the hydroxyl groups of calcitriol could also form hydrogen bonds with Q189, T190, T26 of Mpro (<xref ref-type="sec" rid="s12">Supplementary Figure S6B</xref>). Our results also showed that the amino acid residue VD3 bound to Mpro was consistent with the amino acid residue bound the proto-ligand 2-cyclohexyl-<italic>N</italic>-(pyridin-3-yl) acetamide (GWS) to Mpro, which was E166 (<xref ref-type="sec" rid="s12">Supplementary Figure S6D</xref>).</p>
<fig id="F6" position="float">
<label>FIGURE 6</label>
<caption>
<p>Confirmation of vitamin D3 binding to STAD/COVID-19 targets. <bold>(A)</bold> Molecular docking model of VD3 with SARS-COV-2 Spike RBD/ACE2 complex [PDB: 6LZG, ACE2 (green), SARS-CoV-2 RBD (cyan)] and 2D patterns of bonds in the model. <bold>(B)</bold> Molecular docking model of VD3 with SARS-CoV-2 major protease (PDB: 5R84) and 2D patterns of bonds in the model. <bold>(C)</bold> Molecular docking model of VD3 with PAI1 (PDB: 1A7C) and 2D patterns of bonds in the model.</p>
</caption>
<graphic xlink:href="fphar-13-874637-g006.tif"/>
</fig>
<p>In addition, we analyzed the possible binding between VD3 and the top 5 STAD/COVID-19 core target proteins (IL1A, IL8, ALBU, CSF2, PAI1) identified in the STRING analysis. Similarly, we also considered the binding of calcitriol. Our result showed that VD3 only bind to PAI1, as does calcitriol. Four cavity coordinates were detected by DeepSite in PAI1. We selected the highest scoring cavity 1 for molecular docking (<xref ref-type="sec" rid="s12">Supplementary Figure S4C</xref>). The hydroxyl group of VD3 was bound to Q322 <italic>via</italic> 1 hydrogen bonding to PAI1 (PDB: 1A7C). And hydrophobic interactions were also found (<xref ref-type="fig" rid="F6">Figure 6C</xref>). The hydroxyl groups of calcitriol were bound to N167, Q322, R163 and L163 of PAI1 by hydrogen bonding (<xref ref-type="sec" rid="s12">Supplementary Figure S6C</xref>). The scores of each docking posture were listed in <xref ref-type="table" rid="T3">Table 3</xref>.</p>
<table-wrap id="T3" position="float">
<label>TABLE 3</label>
<caption>
<p>CDOCKER scores of SARS-CoV-2 and PAI1.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th align="left">Ligand Name</th>
<th align="center">Target</th>
<th align="center">PBD ID</th>
<th align="center">CDOCKER Interaction Energy (kcal/mol)</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td align="left">Vitamin D3</td>
<td align="left">SARS-CoV-2 RBD/ACE2</td>
<td align="center">6LZG</td>
<td align="char" char=".">&#x2212;27.9718</td>
</tr>
<tr>
<td align="left">Calcitriol</td>
<td align="left">SARS-CoV-2 RBD/ACE2</td>
<td align="center">6LZG</td>
<td align="char" char=".">&#x2212;32.8289</td>
</tr>
<tr>
<td align="left">Vitamin D3</td>
<td align="left">SARS-CoV-2 Mpro</td>
<td align="center">5R84</td>
<td align="char" char=".">&#x2212;40.8162</td>
</tr>
<tr>
<td align="left">Calcitriol</td>
<td align="left">SARS-CoV-2 Mpro</td>
<td align="center">5R84</td>
<td align="char" char=".">&#x2212;50.7525</td>
</tr>
<tr>
<td align="left">Vitamin D3</td>
<td align="left">PAI1</td>
<td align="center">1A7C</td>
<td align="char" char=".">&#x2212;54.3729</td>
</tr>
<tr>
<td align="left">Calcitriol</td>
<td align="left">PAI1</td>
<td align="center">1A7C</td>
<td align="char" char=".">&#x2212;64.9648</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
</sec>
<sec sec-type="discussion" id="s4">
<title>Discussion</title>
<p>Since the first case of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection was reported in 2019, infections and mortality rates have continued to rise globally. In addition, the specific therapy for COVID-19 is still inconclusive. The SARS-CoV-2 pandemic has proven to be catastrophic. Therefore, it is urgent to find safe and effective anti-COVID-19 drugs and effective targets. SARS-CoV-2 is commonly thought to be transmitted by the respiratory droplet route, but studies have shown that humans may also be infected with SARS-CoV-2 through the gastrointestinal tract (<xref ref-type="bibr" rid="B28">Lamers et al., 2020</xref>; <xref ref-type="bibr" rid="B35">Lin et al., 2020</xref>; <xref ref-type="bibr" rid="B44">Pan et al., 2020</xref>; <xref ref-type="bibr" rid="B53">Wang et al., 2020</xref>; <xref ref-type="bibr" rid="B22">Jiao et al., 2021</xref>). Surprisingly, sputum and feces samples from the COVID-19 patients continued to be positive even after their pharyngeal samples changed from positive to negative (<xref ref-type="bibr" rid="B7">Chen et al., 2020</xref>). With the trend of the COVID-19 pandemic, hospitals have become a high-risk site for SARS-COV-2 infection, so hospitalized patients have become a high-risk group. Among them, the risk of SARS-COV-2 infection in cancer patients has increased dramatically due to factors such as immunosuppression and immune dysfunction (<xref ref-type="bibr" rid="B18">Gonzalez et al., 2018</xref>; <xref ref-type="bibr" rid="B34">Liang et al., 2020</xref>). This forced us to pursue a new approach to treating STAD/COVID-19.</p>
<p>VD3 is the active form of vitamin D with the highest rate of biometabolism and is primarily synthesized by the body itself. VD3 is converted by UV irradiation of 7-dehydrocholesterol, which is found in the epidermis and dermis of most advanced animals. And VD3 is subsequently activated to its powerful hormone form, calcitriol (<xref ref-type="bibr" rid="B16">Gil et al., 2018</xref>). Based on the beneficial effects of VD3 against gastric cancer (<xref ref-type="bibr" rid="B3">Bao et al., 2014</xref>; <xref ref-type="bibr" rid="B30">Li et al., 2017</xref>), Helicobacter pylori (<xref ref-type="bibr" rid="B20">Hu et al., 2019</xref>), anti-inflammatory actions (<xref ref-type="bibr" rid="B27">Krishnan and Feldman, 2011</xref>) and hepatitis C virus (<xref ref-type="bibr" rid="B13">Gal-Tanamy et al., 2011</xref>), we hypothesized that VD3 and calcitriol may have effective pharmacological activity in patients with STAD combined with COVID-19. In this work, we used bioinformatics, network pharmacology and molecular docking to elucidate the molecular biological mechanisms of VD3 or calcitriol for the treatment of STAD/COVID-19. This may provide a new idea to improve the survival rate of STAD/COVID-19 patients and to cut off the transmission of SARS-COV-2 through the gastrointestinal tract.</p>
<p>In this study, 137 intersecting genes of COVID-19 and STAD were obtained through the collection and screening of several databases, of which 71 genes were up-regulated and 66 genes were down-regulated. Notably, four important differential genes were identified based on the results of multivariate Cox proportional risk regression analysis, including <italic>KIT</italic>, <italic>HBA1</italic>, <italic>SERPINE1</italic> and <italic>FKBP10</italic>. We also performed survival curve analysis, and the results revealed that patients with low <italic>SERPINE1</italic>, <italic>FKBP10</italic> and <italic>KIT</italic> levels had better DFS and OS than those with high levels (<italic>p</italic> &#x3c; 0.05). Therefore, the expression of <italic>SERPINE1</italic>, <italic>FKBP10</italic> and <italic>KIT</italic> could be used to predict the prognosis of STAD patients. Next, we combined the 137 DEGs obtained from STAD/COVID-19 samples with VD3-related genes to obtain 60 intersecting genes, and further GO enrichment analysis and KEGG pathway enrichment analysis were performed on these 60 intersecting genes. Similarly, we also considered genes associated with calcitriol. The results suggested that the anti-STAD and anti-COVID19 effects of VD3 were achieved through antiviral effects, anti-inflammatory effects, immunomodulation, and modulation of related signaling pathways. These results suggested that the 60 intersecting genes we obtained may be effective pharmacological targets of VD3 against COVID-19 and STAD. In addition, we found that the anti-COVID-19 and anti-STAD effects of VD3 may be associated with core genes such as <italic>IL1A</italic>, <italic>CXCL8</italic>, <italic>ALB</italic>, <italic>CSF2</italic>, and <italic>SERPINE1</italic>. Next, we speculated that the anti-COVID-19/STAD effects of VD3 might be associated with the core genes <italic>IL1A</italic>, <italic>CXCL8</italic>, <italic>ALB</italic>, <italic>CSF2</italic> and <italic>SERPINE1</italic>, and then did molecular docking to verify the speculation.</p>
<p>The process of SARS-CoV-2 infection could be divided into three steps: attachment and cell entry (S protein and ACE2) (<xref ref-type="bibr" rid="B55">Wrapp et al., 2020</xref>; <xref ref-type="bibr" rid="B58">Xu et al., 2020</xref>), replication and transcription (Mpro) (<xref ref-type="bibr" rid="B33">Li et al., 2021b</xref>), the assembly and release of the mature virus. Therefore, we selected SARS-COV-2 Spike RBD/ACE2 complex (PDB: 6LZG) and SARS-COV-2 Mpro (PDB: 5R84) for molecular docking to simulate the infection process of SARS-COV-2. The results indicated that VD3 had binding activity with SARS-COV-2 RBD/ACE2, Mpro and PAI1. Similarly, we did molecular docking of calcitriol with SARS-COV-2 RBD/ACE2, Mpro and PAI1. These results indicated that either VD3 or calcitriol can effectively bind to specific proteins in the novel coronavirus and has the potential to intervene in the infection process of SARS-CoV-2. Plasminogen activator inhibitor-1 (<italic>PAI1</italic>, aka <italic>SERPINE1</italic>) is a typical member of the Serpin family of proteins (<xref ref-type="bibr" rid="B26">Kellici et al., 2021</xref>). <italic>SERPINE1</italic> acts as an inhibitor of tissue plasminogen activator (tPA) and urokinase plasminogen activator (uPA), preventing plasmin formation and inhibiting fibrinolysis and clot dissolution (<xref ref-type="bibr" rid="B56">Wu et al., 1995</xref>; <xref ref-type="bibr" rid="B52">Urano et al., 2019</xref>). Not surprisingly, <italic>SERPINE1</italic> was identified in the complement and coagulation cascades pathway by KEGG pathway enrichment analysis. A growing number of studies have shown that complement and coagulation cascades direct thrombotic activities in severe COVID-19 patients and also activate neutrophil degranulation (<xref ref-type="bibr" rid="B21">Ibrahim et al., 2004</xref>). Neutrophil degranulation and activation of complements of the complement and coagulation pathway can eventually lead to acute respiratory distress syndrome (ARDS), lung injury, thrombosis and other adverse consequences in COVID-19 patients (<xref ref-type="bibr" rid="B24">Jose and Manuel, 2020</xref>). In addition, a growing body of evidence has demonstrated that <italic>SERPINE1</italic> expression is associated with poor prognosis in patients with breast (<xref ref-type="bibr" rid="B37">Look et al., 2002</xref>), ovarian (<xref ref-type="bibr" rid="B6">Chambers et al., 1998</xref>), colon (<xref ref-type="bibr" rid="B12">Sakakibara et al., 2005</xref>) and gastric (<xref ref-type="bibr" rid="B46">Sakakibara et al., 2006</xref>) cancers. And <italic>SERPINE1</italic> plays multiple roles in human tumorigenesis, such as sustaining proliferative signals (<xref ref-type="bibr" rid="B15">Giacoia et al., 2014</xref>), resisting cell death (<xref ref-type="bibr" rid="B48">Schneider et al., 2008</xref>), promoting angiogenesis (<xref ref-type="bibr" rid="B2">Bajou et al., 2001</xref>), regulating invasion and metastasis (<xref ref-type="bibr" rid="B38">Ma et al., 1997</xref>; <xref ref-type="bibr" rid="B4">Brooks et al., 2000</xref>), and promoting inflammatory responses (<xref ref-type="bibr" rid="B47">Sawdey and Loskutoff, 1991</xref>; <xref ref-type="bibr" rid="B41">Mertens et al., 2006</xref>).</p>
<p>Based on the lock and key principle of ligand-receptor interaction, molecular docking can effectively identify small molecular compounds matching the spatial and electrical characteristics of the active site of the target receptor, which provides a basis for further experiments <italic>in vivo</italic> and <italic>in vitro</italic>. These docking results suggested that VD3 may enable <italic>SERPINE1</italic> to target COVID-19. However, the above results were obtained based on bioinformatics and network pharmacology methods. Since this is a virtual screening method, molecular docking involves unpredictable deviations from reality, which may lead to some errors in <italic>in vivo</italic>/<italic>in vitro</italic> experiments. However, the docking results reflect possible therapeutic mechanisms and provide guidance for animal validation experiments.</p>
</sec>
<sec sec-type="conclusion" id="s5">
<title>Conclusion</title>
<p>In conclusion, the bioinformatics results strongly suggested that antiviral, anti-inflammatory and immunomodulation are key pathways for VD3 in the treatment of STAD/COVID-19. Furthermore, based on the network pharmacology results, we identified effective pharmacological targets of VD3 against STAD/COVID-19, providing new possibilities for further clinical trials.</p>
</sec>
</body>
<back>
<sec id="s6">
<title>Data Availability Statement</title>
<p>The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article/<xref ref-type="sec" rid="s12">Supplementary Material</xref>.</p>
</sec>
<sec id="s7">
<title>Ethics Statement</title>
<p>Since all datasets included in the present study were downloaded from TCGA, additional approval by an ethics committee was not needed. The study was conducted in accordance with Declaration of Helsinki (as revised in 2013).</p>
</sec>
<sec id="s8">
<title>Author Contributions</title>
<p>SW and YJ contributed to conception and design. SW and HG performed the network pharmacology analysis. YJ and YW supervised and wrote the article. SW, XW, XM, LZ, and YX analyzed the data. All authors reviewed the manuscript and approved the final manuscript.</p>
</sec>
<sec id="s9">
<title>Funding</title>
<p>This study was financially supported by the National Natural Science Foundation of China (No. 31970728), the Academic Promotion Program of Shandong First Medical University (No. 2019QL024), the Shandong Provincial Natural Science Foundation of China (Nos. ZR2020LZL005 and ZR2020MH050).</p>
</sec>
<sec sec-type="COI-statement" id="s10">
<title>Conflict of Interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec sec-type="disclaimer" id="s11">
<title>Publisher&#x2019;s Note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<sec id="s12">
<title>Supplementary Material</title>
<p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fphar.2022.874637/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fphar.2022.874637/full&#x23;supplementary-material</ext-link>
</p>
<supplementary-material xlink:href="Table2.XLSX" id="SM1" mimetype="application/XLSX" xmlns:xlink="http://www.w3.org/1999/xlink"/>
<supplementary-material xlink:href="Table4.pdf" id="SM2" mimetype="application/pdf" xmlns:xlink="http://www.w3.org/1999/xlink"/>
<supplementary-material xlink:href="Table3.xlsx" id="SM3" mimetype="application/xlsx" xmlns:xlink="http://www.w3.org/1999/xlink"/>
<supplementary-material xlink:href="Table1.pdf" id="SM4" mimetype="application/pdf" xmlns:xlink="http://www.w3.org/1999/xlink"/>
<supplementary-material xlink:href="DataSheet1.pdf" id="SM5" mimetype="application/pdf" xmlns:xlink="http://www.w3.org/1999/xlink"/>
</sec>
<sec id="s13">
<title>Abbreviations</title>
<p>ACE2, Angiotensin converting enzyme2; BP, biological process; CC, cellular composition; COVID-19, Corona Virus Disease 2019; DEG, differentially expressed genes; GO, Gene Ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes; MF, molecular function; PAI1/SERPINE1, Plasminogen activator inhibitor-1/serpin family E member 1; PPI, Protein-protein interaction; PDB, Protein Data Bank; SARS-CoV-2, Severe acute respiratory syndrome coronavirus 2; STAD, Stomach adenocarcinoma; VD3, vitamin D3.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Arnold</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Abnet</surname>
<given-names>C. C.</given-names>
</name>
<name>
<surname>Neale</surname>
<given-names>R. E.</given-names>
</name>
<name>
<surname>Vignat</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Giovannucci</surname>
<given-names>E. L.</given-names>
</name>
<name>
<surname>McGlynn</surname>
<given-names>K. A.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Global Burden of 5 Major Types of Gastrointestinal Cancer</article-title>. <source>Gastroenterology</source> <volume>159</volume> (<issue>1</issue>), <fpage>335</fpage>&#x2013;<lpage>e15</lpage>. <comment>e15</comment>. <pub-id pub-id-type="doi">10.1053/j.gastro.2020.02.068</pub-id> </citation>
</ref>
<ref id="B2">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bajou</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Masson</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Gerard</surname>
<given-names>R. D.</given-names>
</name>
<name>
<surname>Schmitt</surname>
<given-names>P. M.</given-names>
</name>
<name>
<surname>Albert</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Praus</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2001</year>). <article-title>The Plasminogen Activator Inhibitor PAI-1 Controls <italic>In Vivo</italic> Tumor Vascularization by Interaction with Proteases, Not Vitronectin. Implications for Antiangiogenic Strategies</article-title>. <source>J. Cell Biol</source> <volume>152</volume> (<issue>4</issue>), <fpage>777</fpage>&#x2013;<lpage>784</lpage>. <pub-id pub-id-type="doi">10.1083/jcb.152.4.777</pub-id> </citation>
</ref>
<ref id="B3">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bao</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Tong</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Wei</surname>
<given-names>C.</given-names>
</name>
</person-group> (<year>2014</year>). <article-title>1,25-Dihydroxyvitamin D&#x2083; and Cisplatin Synergistically Induce Apoptosis and Cell Cycle Arrest in Gastric Cancer Cells</article-title>. <source>Int. J. Mol. Med.</source> <volume>33</volume> (<issue>5</issue>), <fpage>1177</fpage>&#x2013;<lpage>1184</lpage>. <pub-id pub-id-type="doi">10.3892/ijmm.2014.1664</pub-id> </citation>
</ref>
<ref id="B4">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brooks</surname>
<given-names>T. D.</given-names>
</name>
<name>
<surname>Slomp</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Quax</surname>
<given-names>P. H.</given-names>
</name>
<name>
<surname>De Bart</surname>
<given-names>A. C.</given-names>
</name>
<name>
<surname>Spencer</surname>
<given-names>M. T.</given-names>
</name>
<name>
<surname>Verheijen</surname>
<given-names>J. H.</given-names>
</name>
<etal/>
</person-group> (<year>2000</year>). <article-title>Antibodies to PAI-1 Alter the Invasive and Migratory Properties of Human Tumour Cells <italic>In Vitro</italic>
</article-title>. <source>Clin. Exp. Metastasis</source> <volume>18</volume> (<issue>6</issue>), <fpage>445</fpage>&#x2013;<lpage>453</lpage>. <pub-id pub-id-type="doi">10.1023/a:1011882421528</pub-id> </citation>
</ref>
<ref id="B5">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cannata-And&#xed;a</surname>
<given-names>J. B.</given-names>
</name>
<name>
<surname>D&#xed;az-Sottolano</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Fern&#xe1;ndez</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Palomo-Antequera</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Herrero-Puente</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Mouzo</surname>
<given-names>R.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>A Single-Oral Bolus of 100,000 IU of Cholecalciferol at Hospital Admission Did Not Improve Outcomes in the COVID-19 Disease: the COVID-VIT-D-A Randomised Multicentre International Clinical Trial</article-title>. <source>BMC Med.</source> <volume>20</volume> (<issue>1</issue>), <fpage>83</fpage>. <pub-id pub-id-type="doi">10.1186/s12916-022-02290-8</pub-id> </citation>
</ref>
<ref id="B6">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chambers</surname>
<given-names>S. K.</given-names>
</name>
<name>
<surname>Ivins</surname>
<given-names>C. M.</given-names>
</name>
<name>
<surname>Carcangiu</surname>
<given-names>M. L.</given-names>
</name>
</person-group> (<year>1998</year>). <article-title>Plasminogen Activator Inhibitor-1 Is an Independent Poor Prognostic Factor for Survival in Advanced Stage Epithelial Ovarian Cancer Patients</article-title>. <source>Int. J. Cancer</source> <volume>79</volume> (<issue>5</issue>), <fpage>449</fpage>&#x2013;<lpage>454</lpage>. <pub-id pub-id-type="doi">10.1002/(sici)1097-0215(19981023)79:5&#x3c;449::aid-ijc1&#x3e;3.0.co;2-0</pub-id> </citation>
</ref>
<ref id="B7">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Pu</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>L.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>SARS-CoV-2-Positive Sputum and Feces after Conversion of Pharyngeal Samples in Patients with COVID-19</article-title>. <source>Ann. Intern. Med.</source> <volume>172</volume> (<issue>12</issue>), <fpage>832</fpage>&#x2013;<lpage>834</lpage>. <pub-id pub-id-type="doi">10.7326/M20-0991</pub-id> </citation>
</ref>
<ref id="B8">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chin</surname>
<given-names>C. H.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>S. H.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>H. H.</given-names>
</name>
<name>
<surname>Ho</surname>
<given-names>C. W.</given-names>
</name>
<name>
<surname>Ko</surname>
<given-names>M. T.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>C. Y.</given-names>
</name>
</person-group> (<year>2014</year>). <article-title>cytoHubba: Identifying Hub Objects and Sub-networks from Complex Interactome</article-title>. <source>BMC Syst. Biol.</source> <volume>8</volume> (<issue>Suppl. 4</issue>), <fpage>S11</fpage>. <pub-id pub-id-type="doi">10.1186/1752-0509-8-S4-S11</pub-id> </citation>
</ref>
<ref id="B9">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Feldman</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Krishnan</surname>
<given-names>A. V.</given-names>
</name>
<name>
<surname>Swami</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Giovannucci</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Feldman</surname>
<given-names>B. J.</given-names>
</name>
</person-group> (<year>2014</year>). <article-title>The Role of Vitamin D in Reducing Cancer Risk and Progression</article-title>. <source>Nat. Rev. Cancer</source> <volume>14</volume> (<issue>5</issue>), <fpage>342</fpage>&#x2013;<lpage>357</lpage>. <pub-id pub-id-type="doi">10.1038/nrc3691</pub-id> </citation>
</ref>
<ref id="B10">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ferrer-Mayorga</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>G&#xf3;mez-L&#xf3;pez</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Barb&#xe1;chano</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Fern&#xe1;ndez-Barral</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Pe&#xf1;a</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Pisano</surname>
<given-names>D. G.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>Vitamin D Receptor Expression and Associated Gene Signature in Tumour Stromal Fibroblasts Predict Clinical Outcome in Colorectal Cancer</article-title>. <source>Gut</source> <volume>66</volume> (<issue>8</issue>), <fpage>1449</fpage>&#x2013;<lpage>1462</lpage>. <pub-id pub-id-type="doi">10.1136/gutjnl-2015-310977</pub-id> </citation>
</ref>
<ref id="B11">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fisher</surname>
<given-names>L. D.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>D. Y.</given-names>
</name>
</person-group> (<year>1999</year>). <article-title>Time-dependent Covariates in the Cox Proportional-Hazards Regression Model</article-title>. <source>Annu. Rev. Public Health</source> <volume>20</volume>, <fpage>145</fpage>&#x2013;<lpage>157</lpage>. <pub-id pub-id-type="doi">10.1146/annurev.publhealth.20.1.145</pub-id> </citation>
</ref>
<ref id="B13">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gal-Tanamy</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Bachmetov</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Ravid</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Koren</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Erman</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Tur-Kaspa</surname>
<given-names>R.</given-names>
</name>
<etal/>
</person-group> (<year>2011</year>). <article-title>Vitamin D: an Innate Antiviral Agent Suppressing Hepatitis C Virus in Human Hepatocytes</article-title>. <source>Hepatology</source> <volume>54</volume> (<issue>5</issue>), <fpage>1570</fpage>&#x2013;<lpage>1579</lpage>. <pub-id pub-id-type="doi">10.1002/hep.24575</pub-id> </citation>
</ref>
<ref id="B14">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ganji</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Al-Obahi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Yusuf</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Dookhy</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>Z.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Serum Vitamin D Is Associated with Improved Lung Function Markers but Not with Prevalence of Asthma, Emphysema, and Chronic Bronchitis</article-title>. <source>Sci. Rep.</source> <volume>10</volume> (<issue>1</issue>), <fpage>11542</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-020-67967-7</pub-id> </citation>
</ref>
<ref id="B15">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Giacoia</surname>
<given-names>E. G.</given-names>
</name>
<name>
<surname>Miyake</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Lawton</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Goodison</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Rosser</surname>
<given-names>C. J.</given-names>
</name>
</person-group> (<year>2014</year>). <article-title>PAI-1 Leads to G1-phase Cell-Cycle Progression through Cyclin D3/cdk4/6 Upregulation</article-title>. <source>Mol. Cancer Res.</source> <volume>12</volume> (<issue>3</issue>), <fpage>322</fpage>&#x2013;<lpage>334</lpage>. <pub-id pub-id-type="doi">10.1158/1541-7786.MCR-13-0543</pub-id> </citation>
</ref>
<ref id="B16">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gil</surname>
<given-names>&#xc1;.</given-names>
</name>
<name>
<surname>Plaza-Diaz</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Mesa</surname>
<given-names>M. D.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Vitamin D: Classic and Novel Actions</article-title>. <source>Ann. Nutr. Metab.</source> <volume>72</volume> (<issue>2</issue>), <fpage>87</fpage>&#x2013;<lpage>95</lpage>. <pub-id pub-id-type="doi">10.1159/000486536</pub-id> </citation>
</ref>
<ref id="B17">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Giobbe</surname>
<given-names>G. G.</given-names>
</name>
<name>
<surname>Bonfante</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Jones</surname>
<given-names>B. C.</given-names>
</name>
<name>
<surname>Gagliano</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Luni</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Zambaiti</surname>
<given-names>E.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>SARS-CoV-2 Infection and Replication in Human Gastric Organoids</article-title>. <source>Nat. Commun.</source> <volume>12</volume> (<issue>1</issue>), <fpage>6610</fpage>. <pub-id pub-id-type="doi">10.1038/s41467-021-26762-2</pub-id> </citation>
</ref>
<ref id="B18">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gonzalez</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Hagerling</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Werb</surname>
<given-names>Z.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Roles of the Immune System in Cancer: from Tumor Initiation to Metastatic Progression</article-title>. <source>Genes Dev.</source> <volume>32</volume> (<issue>19-20</issue>), <fpage>1267</fpage>&#x2013;<lpage>1284</lpage>. <pub-id pub-id-type="doi">10.1101/gad.314617.118</pub-id> </citation>
</ref>
<ref id="B19">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hopkins</surname>
<given-names>A. L.</given-names>
</name>
</person-group> (<year>2008</year>). <article-title>Network Pharmacology: the Next Paradigm in Drug Discovery</article-title>. <source>Nat. Chem. Biol.</source> <volume>4</volume> (<issue>11</issue>), <fpage>682</fpage>&#x2013;<lpage>690</lpage>. <pub-id pub-id-type="doi">10.1038/nchembio.118</pub-id> </citation>
</ref>
<ref id="B20">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hu</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>M. X.</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>X. D.</given-names>
</name>
<name>
<surname>Xiao</surname>
<given-names>Z. G.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Vitamin D3 Activates the Autolysosomal Degradation Function against <italic>Helicobacter pylori</italic> through the PDIA3 Receptor in Gastric Epithelial Cells</article-title>. <source>Autophagy</source> <volume>15</volume> (<issue>4</issue>), <fpage>707</fpage>&#x2013;<lpage>725</lpage>. <pub-id pub-id-type="doi">10.1080/15548627.2018.1557835</pub-id> </citation>
</ref>
<ref id="B21">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ibrahim</surname>
<given-names>F. B.</given-names>
</name>
<name>
<surname>Pang</surname>
<given-names>S. J.</given-names>
</name>
<name>
<surname>Melendez</surname>
<given-names>A. J.</given-names>
</name>
</person-group> (<year>2004</year>). <article-title>Anaphylatoxin Signaling in Human Neutrophils. A Key Role for Sphingosine Kinase</article-title>. <source>J. Biol. Chem.</source> <volume>279</volume> (<issue>43</issue>), <fpage>44802</fpage>&#x2013;<lpage>44811</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M403977200</pub-id> </citation>
</ref>
<ref id="B22">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jiao</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>The Gastrointestinal Tract Is an Alternative Route for SARS-CoV-2 Infection in a Nonhuman Primate Model</article-title>. <source>Gastroenterology</source> <volume>160</volume> (<issue>5</issue>), <fpage>1647</fpage>&#x2013;<lpage>1661</lpage>. <pub-id pub-id-type="doi">10.1053/j.gastro.2020.12.001</pub-id> </citation>
</ref>
<ref id="B23">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jim&#xe9;nez</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Doerr</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Mart&#xed;nez-Rosell</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Rose</surname>
<given-names>A. S.</given-names>
</name>
<name>
<surname>De Fabritiis</surname>
<given-names>G.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>DeepSite: Protein-Binding Site Predictor Using 3D-Convolutional Neural Networks</article-title>. <source>Bioinformatics (Oxford, England)</source> <volume>33</volume> (<issue>19</issue>), <fpage>3036</fpage>&#x2013;<lpage>3042</lpage>. <pub-id pub-id-type="doi">10.1093/bioinformatics/btx350</pub-id> </citation>
</ref>
<ref id="B24">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jose</surname>
<given-names>R. J.</given-names>
</name>
<name>
<surname>Manuel</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>COVID-19 Cytokine Storm: the Interplay between Inflammation and Coagulation</article-title>. <source>Lancet Respir. Med.</source> <volume>8</volume> (<issue>6</issue>), <fpage>e46</fpage>&#x2013;<lpage>e7</lpage>. <pub-id pub-id-type="doi">10.1016/S2213-2600(20)30216-2</pub-id> </citation>
</ref>
<ref id="B25">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kellenberger</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Muller</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Schalon</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Bret</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Foata</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Rognan</surname>
<given-names>D.</given-names>
</name>
</person-group> (<year>2006</year>). <article-title>Sc-PDB: an Annotated Database of Druggable Binding Sites from the Protein Data Bank</article-title>. <source>J. Chem. Inf. Model.</source> <volume>46</volume> (<issue>2</issue>), <fpage>717</fpage>&#x2013;<lpage>727</lpage>. <pub-id pub-id-type="doi">10.1021/ci050372x</pub-id> </citation>
</ref>
<ref id="B26">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kellici</surname>
<given-names>T. F.</given-names>
</name>
<name>
<surname>Pilka</surname>
<given-names>E. S.</given-names>
</name>
<name>
<surname>Bodkin</surname>
<given-names>M. J.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Small-molecule Modulators of Serine Protease Inhibitor Proteins (Serpins)</article-title>. <source>Drug Discov. Today</source> <volume>26</volume> (<issue>2</issue>), <fpage>442</fpage>&#x2013;<lpage>454</lpage>. <pub-id pub-id-type="doi">10.1016/j.drudis.2020.11.012</pub-id> </citation>
</ref>
<ref id="B27">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Krishnan</surname>
<given-names>A. V.</given-names>
</name>
<name>
<surname>Feldman</surname>
<given-names>D.</given-names>
</name>
</person-group> (<year>2011</year>). <article-title>Mechanisms of the Anti-cancer and Anti-inflammatory Actions of Vitamin D</article-title>. <source>Annu. Rev. Pharmacol. Toxicol.</source> <volume>51</volume>, <fpage>311</fpage>&#x2013;<lpage>336</lpage>. <pub-id pub-id-type="doi">10.1146/annurev-pharmtox-010510-100611</pub-id> </citation>
</ref>
<ref id="B28">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lamers</surname>
<given-names>M. M.</given-names>
</name>
<name>
<surname>Beumer</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>van der Vaart</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Knoops</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Puschhof</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Breugem</surname>
<given-names>T. I.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>SARS-CoV-2 Productively Infects Human Gut Enterocytes</article-title>. <source>Science</source> <volume>369</volume> (<issue>6499</issue>), <fpage>50</fpage>&#x2013;<lpage>54</lpage>. <pub-id pub-id-type="doi">10.1126/science.abc1669</pub-id> </citation>
</ref>
<ref id="B29">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lan</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Ge</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Shan</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Fan</surname>
<given-names>S.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Structure of the SARS-CoV-2 Spike Receptor-Binding Domain Bound to the ACE2 Receptor</article-title>. <source>Nature</source> <volume>581</volume> (<issue>7807</issue>), <fpage>215</fpage>&#x2013;<lpage>220</lpage>. <pub-id pub-id-type="doi">10.1038/s41586-020-2180-5</pub-id> </citation>
</ref>
<ref id="B30">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Xiao</surname>
<given-names>Z.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>1,25-Dihydroxyvitamin D3 Suppresses Gastric Cancer Cell Growth through VDR- and Mutant P53-Mediated Induction of P21</article-title>. <source>Life Sci.</source> <volume>179</volume>, <fpage>88</fpage>&#x2013;<lpage>97</lpage>. <pub-id pub-id-type="doi">10.1016/j.lfs.2017.04.021</pub-id> </citation>
</ref>
<ref id="B31">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Liang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Su</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Lai</surname>
<given-names>K. P.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Network Pharmacology and Bioinformatics Analyses Identify Intersection Genes of Niacin and COVID-19 as Potential Therapeutic Targets</article-title>. <source>Brief Bioinform</source> <volume>22</volume> (<issue>2</issue>), <fpage>1279</fpage>&#x2013;<lpage>1290</lpage>. <pub-id pub-id-type="doi">10.1093/bib/bbaa300</pub-id> </citation>
</ref>
<ref id="B32">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Ji</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>L.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Pharmacological Biotargets and the Molecular Mechanisms of Oxyresveratrol Treating Colorectal Cancer: Network and Experimental Analyses</article-title>. <source>Biofactors</source> <volume>46</volume> (<issue>1</issue>), <fpage>158</fpage>&#x2013;<lpage>167</lpage>. <pub-id pub-id-type="doi">10.1002/biof.1583</pub-id> </citation>
</ref>
<ref id="B33">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Qiu</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Cao</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Q.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Chemical Composition and Pharmacological Mechanism of Ephedra-glycyrrhiza Drug Pair against Coronavirus Disease 2019 (COVID-19)</article-title>. <source>Aging (Albany NY)</source> <volume>13</volume> (<issue>4</issue>), <fpage>4811</fpage>&#x2013;<lpage>4830</lpage>. <pub-id pub-id-type="doi">10.18632/aging.202622</pub-id> </citation>
</ref>
<ref id="B34">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liang</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Guan</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>K.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Cancer Patients in SARS-CoV-2 Infection: a Nationwide Analysis in China</article-title>. <source>Lancet Oncol.</source> <volume>21</volume> (<issue>3</issue>), <fpage>335</fpage>&#x2013;<lpage>337</lpage>. <pub-id pub-id-type="doi">10.1016/S1470-2045(20)30096-6</pub-id> </citation>
</ref>
<ref id="B35">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lin</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Fang</surname>
<given-names>Z.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Gastrointestinal Symptoms of 95 Cases with SARS-CoV-2 Infection</article-title>. <source>Gut</source> <volume>69</volume> (<issue>6</issue>), <fpage>997</fpage>&#x2013;<lpage>1001</lpage>. <pub-id pub-id-type="doi">10.1136/gutjnl-2020-321013</pub-id> </citation>
</ref>
<ref id="B36">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Ning</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Gali</surname>
<given-names>N. K.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Aerodynamic Analysis of SARS-CoV-2 in Two Wuhan Hospitals</article-title>. <source>Nature</source> <volume>582</volume> (<issue>7813</issue>), <fpage>557</fpage>&#x2013;<lpage>560</lpage>. <pub-id pub-id-type="doi">10.1038/s41586-020-2271-3</pub-id> </citation>
</ref>
<ref id="B37">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Look</surname>
<given-names>M. P.</given-names>
</name>
<name>
<surname>van Putten</surname>
<given-names>W. L.</given-names>
</name>
<name>
<surname>Duffy</surname>
<given-names>M. J.</given-names>
</name>
<name>
<surname>Harbeck</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Christensen</surname>
<given-names>I. J.</given-names>
</name>
<name>
<surname>Thomssen</surname>
<given-names>C.</given-names>
</name>
<etal/>
</person-group> (<year>2002</year>). <article-title>Pooled Analysis of Prognostic Impact of Urokinase-type Plasminogen Activator and its Inhibitor PAI-1 in 8377 Breast Cancer Patients</article-title>. <source>J. Natl. Cancer Inst.</source> <volume>94</volume> (<issue>2</issue>), <fpage>116</fpage>&#x2013;<lpage>128</lpage>. <pub-id pub-id-type="doi">10.1093/jnci/94.2.116</pub-id> </citation>
</ref>
<ref id="B38">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ma</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Gerard</surname>
<given-names>R. D.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>X. Y.</given-names>
</name>
<name>
<surname>Alizadeh</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Niederkorn</surname>
<given-names>J. Y.</given-names>
</name>
</person-group> (<year>1997</year>). <article-title>Inhibition of Metastasis of Intraocular Melanomas by Adenovirus-Mediated Gene Transfer of Plasminogen Activator Inhibitor Type 1 (PAI-1) in an Athymic Mouse Model</article-title>. <source>Blood</source> <volume>90</volume> (<issue>7</issue>), <fpage>2738</fpage>&#x2013;<lpage>2746</lpage>. <pub-id pub-id-type="doi">10.1182/blood.v90.7.2738</pub-id> </citation>
</ref>
<ref id="B39">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Maghbooli</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Sahraian</surname>
<given-names>M. A.</given-names>
</name>
<name>
<surname>Ebrahimi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Pazoki</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kafan</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Tabriz</surname>
<given-names>H. M.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Vitamin D Sufficiency, a Serum 25-hydroxyvitamin D at Least 30 ng/mL Reduced Risk for Adverse Clinical Outcomes in Patients with COVID-19 Infection</article-title>. <source>PloS one</source> <volume>15</volume> (<issue>9</issue>), <fpage>e0239799</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0239799</pub-id> </citation>
</ref>
<ref id="B40">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Martineau</surname>
<given-names>A. R.</given-names>
</name>
<name>
<surname>Jolliffe</surname>
<given-names>D. A.</given-names>
</name>
<name>
<surname>Greenberg</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Aloia</surname>
<given-names>J. F.</given-names>
</name>
<name>
<surname>Bergman</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Dubnov-Raz</surname>
<given-names>G.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Vitamin D Supplementation to Prevent Acute Respiratory Infections: Individual Participant Data Meta-Analysis</article-title>. <source>Health Technol. Assess.</source> <volume>23</volume> (<issue>2</issue>), <fpage>1</fpage>&#x2013;<lpage>44</lpage>. <pub-id pub-id-type="doi">10.3310/hta23020</pub-id> </citation>
</ref>
<ref id="B41">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mertens</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Verrijken</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Michiels</surname>
<given-names>J. J.</given-names>
</name>
<name>
<surname>Van der Planken</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ruige</surname>
<given-names>J. B.</given-names>
</name>
<name>
<surname>Van Gaal</surname>
<given-names>L. F.</given-names>
</name>
</person-group> (<year>2006</year>). <article-title>Among Inflammation and Coagulation Markers, PAI-1 Is a True Component of the Metabolic Syndrome</article-title>. <source>Int. J. Obes. (Lond)</source> <volume>30</volume> (<issue>8</issue>), <fpage>1308</fpage>&#x2013;<lpage>1314</lpage>. <pub-id pub-id-type="doi">10.1038/sj.ijo.0803189</pub-id> </citation>
</ref>
<ref id="B42">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Merzon</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Tworowski</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Gorohovski</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Vinker</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Golan Cohen</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Green</surname>
<given-names>I.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Low Plasma 25(OH) Vitamin D Level Is Associated with Increased Risk of COVID-19 Infection: an Israeli Population-Based Study</article-title>. <source>FEBS J.</source> <volume>287</volume> (<issue>17</issue>), <fpage>3693</fpage>&#x2013;<lpage>3702</lpage>. <pub-id pub-id-type="doi">10.1111/febs.15495</pub-id> </citation>
</ref>
<ref id="B43">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mondul</surname>
<given-names>A. M.</given-names>
</name>
<name>
<surname>Weinstein</surname>
<given-names>S. J.</given-names>
</name>
<name>
<surname>Moy</surname>
<given-names>K. A.</given-names>
</name>
<name>
<surname>M&#xe4;nnist&#xf6;</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Albanes</surname>
<given-names>D.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>Circulating 25-Hydroxyvitamin D and Prostate Cancer Survival</article-title>. <source>Cancer Epidemiol. Biomarkers Prev.</source> <volume>25</volume> (<issue>4</issue>), <fpage>665</fpage>&#x2013;<lpage>669</lpage>. <pub-id pub-id-type="doi">10.1158/1055-9965.EPI-15-0991</pub-id> </citation>
</ref>
<ref id="B44">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pan</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Mu</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Yan</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Clinical Characteristics of COVID-19 Patients with Digestive Symptoms in Hubei, China: A Descriptive, Cross-Sectional, Multicenter Study</article-title>. <source>Am. J. Gastroenterol.</source> <volume>115</volume> (<issue>5</issue>), <fpage>766</fpage>&#x2013;<lpage>773</lpage>. <pub-id pub-id-type="doi">10.14309/ajg.0000000000000620</pub-id> </citation>
</ref>
<ref id="B45">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pereira</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Larriba</surname>
<given-names>M. J.</given-names>
</name>
<name>
<surname>Mu&#xf1;oz</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2012</year>). <article-title>Vitamin D and colon Cancer</article-title>. <source>Endocr. Relat. Cancer</source> <volume>19</volume> (<issue>3</issue>), <fpage>R51</fpage>&#x2013;<lpage>R71</lpage>. <pub-id pub-id-type="doi">10.1530/ERC-11-0388</pub-id> </citation>
</ref>
<ref id="B12">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sakakibara</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Hibi</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Koike</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Fujiwara</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kodera</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Ito</surname>
<given-names>K.</given-names>
</name>
<etal/>
</person-group> (<year>2005</year>). <article-title>Plasminogen Activator Inhibitor-1 as a Potential Marker for the Malignancy of Colorectal Cancer</article-title>. <source>Br. J. Cancer</source> <volume>93</volume> (<issue>7</issue>), <fpage>799</fpage>&#x2013;<lpage>803</lpage>. <pub-id pub-id-type="doi">10.1038/sj.bjc.6602743</pub-id> </citation>
</ref>
<ref id="B46">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sakakibara</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Hibi</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Koike</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Fujiwara</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kodera</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Ito</surname>
<given-names>K.</given-names>
</name>
<etal/>
</person-group> (<year>2006</year>). <article-title>Plasminogen Activator Inhibitor-1 as a Potential Marker for the Malignancy of Gastric Cancer</article-title>. <source>Cancer Sci.</source> <volume>97</volume> (<issue>5</issue>), <fpage>395</fpage>&#x2013;<lpage>399</lpage>. <pub-id pub-id-type="doi">10.1111/j.1349-7006.2006.00185.x</pub-id> </citation>
</ref>
<ref id="B47">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sawdey</surname>
<given-names>M. S.</given-names>
</name>
<name>
<surname>Loskutoff</surname>
<given-names>D. J.</given-names>
</name>
</person-group> (<year>1991</year>). <article-title>Regulation of Murine Type 1 Plasminogen Activator Inhibitor Gene Expression <italic>In Vivo</italic>. Tissue Specificity and Induction by Lipopolysaccharide, Tumor Necrosis Factor-Alpha, and Transforming Growth Factor-Beta</article-title>. <source>J. Clin. Invest.</source> <volume>88</volume> (<issue>4</issue>), <fpage>1346</fpage>&#x2013;<lpage>1353</lpage>. <pub-id pub-id-type="doi">10.1172/JCI115440</pub-id> </citation>
</ref>
<ref id="B48">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schneider</surname>
<given-names>D. J.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Sobel</surname>
<given-names>B. E.</given-names>
</name>
</person-group> (<year>2008</year>). <article-title>The Effect of Plasminogen Activator Inhibitor Type 1 on Apoptosis</article-title>. <source>Thromb. Haemost.</source> <volume>100</volume> (<issue>6</issue>), <fpage>1037</fpage>&#x2013;<lpage>1040</lpage>. </citation>
</ref>
<ref id="B49">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Singh</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Rupesh</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Pandit</surname>
<given-names>S. B.</given-names>
</name>
<name>
<surname>Chattopadhyay</surname>
<given-names>K.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Curcumin Inhibits Membrane-Damaging Pore-Forming Function of the &#x3b2;-Barrel Pore-Forming Toxin <italic>Vibrio cholerae</italic> Cytolysin</article-title>. <source>Front. Microbiol.</source> <volume>12</volume>, <fpage>809782</fpage>. <pub-id pub-id-type="doi">10.3389/fmicb.2021.809782</pub-id> </citation>
</ref>
<ref id="B50">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Swami</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Krishnan</surname>
<given-names>A. V.</given-names>
</name>
<name>
<surname>Feldman</surname>
<given-names>D.</given-names>
</name>
</person-group> (<year>2000</year>). <article-title>1alpha,25-Dihydroxyvitamin D3 Down-Regulates Estrogen Receptor Abundance and Suppresses Estrogen Actions in MCF-7 Human Breast Cancer Cells</article-title>. <source>Clin. Cancer Res.</source> <volume>6</volume> (<issue>8</issue>), <fpage>3371</fpage>&#x2013;<lpage>3379</lpage>. </citation>
</ref>
<ref id="B51">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tang</surname>
<given-names>J. W.</given-names>
</name>
<name>
<surname>Tambyah</surname>
<given-names>P. A.</given-names>
</name>
<name>
<surname>Hui</surname>
<given-names>D. S. C.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Emergence of a Novel Coronavirus Causing Respiratory Illness from Wuhan, China</article-title>. <source>J. Infect.</source> <volume>80</volume> (<issue>3</issue>), <fpage>350</fpage>&#x2013;<lpage>371</lpage>. <pub-id pub-id-type="doi">10.1016/j.jinf.2020.01.014</pub-id> </citation>
</ref>
<ref id="B52">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Urano</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Suzuki</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Iwaki</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Sano</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Honkura</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Castellino</surname>
<given-names>F. J.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Recognition of Plasminogen Activator Inhibitor Type 1 as the Primary Regulator of Fibrinolysis</article-title>. <source>Curr. Drug Targets</source> <volume>20</volume> (<issue>16</issue>), <fpage>1695</fpage>&#x2013;<lpage>1701</lpage>. <pub-id pub-id-type="doi">10.2174/1389450120666190715102510</pub-id> </citation>
</ref>
<ref id="B53">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>G.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Detection of SARS-CoV-2 in Different Types of Clinical Specimens</article-title>. <source>Jama</source> <volume>323</volume> (<issue>18</issue>), <fpage>1843</fpage>&#x2013;<lpage>1844</lpage>. <pub-id pub-id-type="doi">10.1001/jama.2020.3786</pub-id> </citation>
</ref>
<ref id="B54">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wierbowski</surname>
<given-names>S. D.</given-names>
</name>
<name>
<surname>Liang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Gupta</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Andre</surname>
<given-names>N. M.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>A 3D Structural SARS-CoV-2-Human Interactome to Explore Genetic and Drug Perturbations</article-title>. <source>Nat. Methods</source> <volume>18</volume> (<issue>12</issue>), <fpage>1477</fpage>&#x2013;<lpage>1488</lpage>. <pub-id pub-id-type="doi">10.1038/s41592-021-01318-w</pub-id> </citation>
</ref>
<ref id="B55">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wrapp</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Corbett</surname>
<given-names>K. S.</given-names>
</name>
<name>
<surname>Goldsmith</surname>
<given-names>J. A.</given-names>
</name>
<name>
<surname>Hsieh</surname>
<given-names>C. L.</given-names>
</name>
<name>
<surname>Abiona</surname>
<given-names>O.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Cryo-EM Structure of the 2019-nCoV Spike in the Prefusion Conformation</article-title>. <source>Science</source> <volume>367</volume> (<issue>6483</issue>), <fpage>1260</fpage>&#x2013;<lpage>1263</lpage>. <pub-id pub-id-type="doi">10.1126/science.abb2507</pub-id> </citation>
</ref>
<ref id="B56">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Urano</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Ihara</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Takada</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Fujie</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Shikimori</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>1995</year>). <article-title>The Cleavage and Inactivation of Plasminogen Activator Inhibitor Type 1 by Neutrophil Elastase: the Evaluation of its Physiologic Relevance in Fibrinolysis</article-title>. <source>Blood</source> <volume>86</volume> (<issue>3</issue>), <fpage>1056</fpage>&#x2013;<lpage>1061</lpage>. <pub-id pub-id-type="doi">10.1182/blood.v86.3.1056.bloodjournal8631056</pub-id> </citation>
</ref>
<ref id="B57">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Luo</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>H.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Vitamin D Alleviates Lipopolysaccharide-induced A-cute L-ung I-njury via R-egulation of the R-enin-angiotensin S-ystem</article-title>. <source>Mol. Med. Rep.</source> <volume>16</volume> (<issue>5</issue>), <fpage>7432</fpage>&#x2013;<lpage>7438</lpage>. <pub-id pub-id-type="doi">10.3892/mmr.2017.7546</pub-id> </citation>
</ref>
<ref id="B58">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Feng</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>X.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Evolution of the Novel Coronavirus from the Ongoing Wuhan Outbreak and Modeling of its Spike Protein for Risk of Human Transmission</article-title>. <source>Sci. China Life Sci.</source> <volume>63</volume> (<issue>3</issue>), <fpage>457</fpage>&#x2013;<lpage>460</lpage>. <pub-id pub-id-type="doi">10.1007/s11427-020-1637-5</pub-id> </citation>
</ref>
<ref id="B59">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zardecki</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Dutta</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Goodsell</surname>
<given-names>D. S.</given-names>
</name>
<name>
<surname>Lowe</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Voigt</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Burley</surname>
<given-names>S. K.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>PDB-101: Educational Resources Supporting Molecular Explorations through Biology and Medicine</article-title>. <source>Protein Sci.</source> <volume>31</volume> (<issue>1</issue>), <fpage>129</fpage>&#x2013;<lpage>140</lpage>. <comment>a publication of the Protein Society</comment>. <pub-id pub-id-type="doi">10.1002/pro.4200</pub-id> </citation>
</ref>
<ref id="B60">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>H.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Excretion of SARS-CoV-2 through Faecal Specimens</article-title>. <source>Emerg. Microbes Infect.</source> <volume>9</volume> (<issue>1</issue>), <fpage>2501</fpage>&#x2013;<lpage>2508</lpage>. <pub-id pub-id-type="doi">10.1080/22221751.2020.1844551</pub-id> </citation>
</ref>
<ref id="B61">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhou</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Min</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>S.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Vitamin D3 Inhibits <italic>Helicobacter pylori</italic> Infection by Activating the VitD3/VDR-CAMP Pathway in Mice</article-title>. <source>Front Cell Infect Microbiol</source> <volume>10</volume>, <fpage>566730</fpage>. <pub-id pub-id-type="doi">10.3389/fcimb.2020.566730</pub-id> </citation>
</ref>
</ref-list>
</back>
</article>